Exercise intolerance

How long might your dog live? New study calculates life expectancy for different breeds

Retrieved on: 
Monday, February 5, 2024
Male, Life expectancy, Life, Human, Research, Cattle, Animal welfare, Dog, Scientific Reports, Animal Welfare Act, Organic, Animal, Trust, Database, Dogs Trust, Exercise intolerance, Female, Risk, Death, Ethics, Breeding, Kennel, Pet, Retching, Hunting

We have life expectancy tables and research for humans that show how long we might be expected to live according to a range of factors.

Key Points: 
  • We have life expectancy tables and research for humans that show how long we might be expected to live according to a range of factors.
  • But there has been very little research into dog life expectancy that considered how different factors affect lifespan.
  • The researchers then calculated median life expectancy for all breeds individually and then for the crossbreed group.
  • Finally, they calculated life expectancy for each combination of sex, size and head shape.

How long do dogs live?

  • This study from researchers at the Dogs Trust provides us with new information about the life expectancy of our canine companions.
  • The researchers found that small, long-nosed female dogs tended to have the longest lifespans among pure breeds overall, with a median lifespan of 13.3 years.
  • But breeds with flat-faces had a median lifespan of 11.2 years, and a 40% increased risk of shorter lives than dogs with medium-length snouts, such as spaniels.
  • Pure breeds had a higher median life expectancy than crossbreeds (12.7 years compared to 12.0 years), while female dogs had a slightly higher median life expectancy than males (12.7 years compared to 12.4 years).

The ethics of ageing

  • These dogs have become fashionable and highly prized as pets, but are prone to various health problems, including brachycephalic obstructive airway syndrome (Boas).
  • This potentially life-threatening condition includes symptoms such as panting, overheating, exercise intolerance, retching, gastrointestinal signs and disturbed sleep patterns.
  • So for some of these dogs, their life is potentially marked by suffering.
  • This raises some questions about dog ownership and the ethics of breeding dogs likely to suffer from Boas.


Angus Nurse has previously received funding from the Department for Environment Food and Rural Affairs to investigate the issue of dangerous dogs and responsible dog ownership.

DrTalks Presents Heal Your Thyroid & Reverse Hashimoto's Summit to Take Place Virtually on July 18 - 24, 2023.

Retrieved on: 
Thursday, April 27, 2023
Exercise, Emergency medicine, Depression, Fatigue, Osteopathic medicine in the United States, Social Emergency Medicine, Cardiac output, Diet, Life, Arthralgia, University, Hair loss, LECOM, Alternative medicine, Teaching, EM, Saint Vincent, Ataxia, St. Vincent's, Mercy Hospital, Woman, Hashimoto's thyroiditis, Research, Multimedia, Newsroom, Exercise intolerance, Weight gain, Thyroid, Heal, Amnesia, Health, Chronic pain, Mental health, Summit, Skin, Medicine, Syndrome, Nursing, Hospital

CARLSBAD, Calif., April 27, 2023 /PRNewswire/ -- DrTalks is excited to announce its upcoming virtual summit, the Heal Your Thyroid & Reverse Hashimoto's Summit , taking place from July 18 - 24, 2023.

Key Points: 
  • CARLSBAD, Calif., April 27, 2023 /PRNewswire/ -- DrTalks is excited to announce its upcoming virtual summit, the Heal Your Thyroid & Reverse Hashimoto's Summit , taking place from July 18 - 24, 2023.
  • The summit is aimed at providing valuable information to empower attendees to get to the root of their Hashimoto's, reverse symptoms, and heal their thyroid.
  • The summit will cover the impact of Hashimoto's symptoms and teach holistic Hashimoto's treatment methods that improve physical and mental health.
  • For more information about the Heal Your Thyroid & Reverse Hashimoto's Summit , please visit https://summits.drtalks.com/reverse-hashimotos-summit/ .

UNITED MITOCHONDRIAL DISEASE FOUNDATION ANNOUNCES NO-COST MITOCHONDRIAL DISEASE GENETIC TESTING PROGRAM

Retrieved on: 
Thursday, April 13, 2023
UMDF, Food, Independent Healthcare Providers Network, Education, Mitochondrion, NGS, Myopathy, Genetic testing, Research, Brain, Privacy, Confidentiality, Exercise intolerance, Pain, Muscle weakness, Patient, Diagnosis, Mitochondrial disease, FDA, Fatigue, Disease, Pharmaceutical industry, Dietary supplement

PITTSBURGH, April 13, 2023 /PRNewswire/ -- The United Mitochondrial Disease Foundation (UMDF), a non-profit organization working to promote research and education for the diagnosis, treatment and cure of mitochondrial diseases, today announced the launch of a no-cost genetic testing program for eligible patients with suspected primary mitochondrial diseases.

Key Points: 
  • PITTSBURGH, April 13, 2023 /PRNewswire/ -- The United Mitochondrial Disease Foundation (UMDF), a non-profit organization working to promote research and education for the diagnosis, treatment and cure of mitochondrial diseases, today announced the launch of a no-cost genetic testing program for eligible patients with suspected primary mitochondrial diseases.
  • The program is aimed at assisting healthcare providers in obtaining a molecular genetic diagnosis for patients who show signs or symptoms of having a primary mitochondrial disease.
  • The no-cost genetic testing program is made possible by a grant from our collaborator and Founding Sponsor Reneo Pharmaceuticals, Inc.
    "A genetic diagnosis is critical for mitochondrial disease patients.
  • It is estimated that fewer than half of patients with primary mitochondrial disease have a confirmed genetic diagnosis.

Veterinary Dentistry Specialists in Mt. Laurel, NJ, Adds a Veterinary Cardiologist to Team of Board-Certified Specialists in Dentistry and Anesthesia

Retrieved on: 
Monday, April 10, 2023
Health, Consumer, Surgery, Other Health, Dental, Pets, Veterinary, Blood pressure, Holter, University, Heart, VDS, Dog, Professional, Echocardiography, Veterinary dentistry, Blue Pearl, VMD, Exercise intolerance, Cough, Anesthesia, Journal of Veterinary Internal Medicine, University of Pennsylvania School of Veterinary Medicine, Patient, Risk, Cardiology, Pericardial effusion, Heart murmur, Abdomen, Electrocardiography, Diplomate of National Board, Heart rate, American College, Veterinary medicine, DVM, Anesthesiology, Cat, Dentistry, Medical imaging

Laurel, NJ, office of Veterinary Dentistry Specialists (VDS), a veterinary dentistry and oral surgery practice, has added board-certified veterinary cardiologist Megan King, VMD, DACVIM (Cardiology), to its roster of dental and anesthesia specialists.

Key Points: 
  • Laurel, NJ, office of Veterinary Dentistry Specialists (VDS), a veterinary dentistry and oral surgery practice, has added board-certified veterinary cardiologist Megan King, VMD, DACVIM (Cardiology), to its roster of dental and anesthesia specialists.
  • Adding comprehensive outpatient veterinary cardiology services makes VDS the first and only veterinary dentistry and oral surgery practice in the nation with anesthesiology and cardiology specialists available to care for each patient.
  • Cardiology services are also available for pet patients who do not need dentistry services.
  • She then earned Diplomate status by becoming board certified in veterinary cardiology by the American College of Veterinary Internal Medicine.

BE YOUR PET'S VALENTINE - SUPPORT THEIR HEART HEALTH THIS FEBRUARY

Retrieved on: 
Monday, February 13, 2023
Science, Exercise intolerance, Life, DVM, Cat, Human, Veterinarian, Animal, Veterinary medicine, Pain, Heart, Central Organization of Trade Unions (Kenya), Patient, EKG, Cardiology, Hyperthyroidism, Anemia, Sudden death, VMX, Hypertrophic cardiomyopathy, Male, X-ray, Death, Exercise, Learning, Quality of life, Pet, MS, Heart murmur, Colorado State University, Dog, Fever, Cough, Medical imaging, Dietary supplement

ORLANDO, Fla., Feb. 13, 2023 /PRNewswire/ -- Your dog's heart speeds up every time you get home, ready for a game of fetch or cuddles on the couch. To keep your furry best friend active and happy for as long as possible, it is important to care for their health year-round. This month, the NAVC highlights the importance of cardiovascular health for our nonhuman family members.

Key Points: 
  • This month, the NAVC highlights the importance of cardiovascular health for our nonhuman family members.
  • Many forms of heart disease found in humans can be found in dogs and cats but treatment can vary from human patients.
  • "Having your veterinarian listen to your dog's heart on an annual basis is critical to detect new heart murmurs or abnormal heart rhythms that may be the first sign that heart disease is present."
  • Hypertrophic Cardiomyopathy - or the thickening of the heart muscle - is the most common heart disease in cats and presents most commonly in middle-aged male cats.

Reneo Pharmaceuticals Reports Third Quarter 2022 Financial Results

Retrieved on: 
Tuesday, November 8, 2022
Myopathy, Gene, Death, Severe cognitive impairment, Brain, Company, Program, Mitochondrion, A-DNA, Conference, Security (finance), Complete Genomics, Enzyme, Muscle, INFORM, Hypoglycemia, Lethargy, U.S. Securities and Exchange Commission, Research, Lotte New York Palace Hotel, Sudden death, Patient, CEO, Metabolism, Private Securities Litigation Reform Act, Total permanent disability insurance, Protein, STRIDE, Nasdaq, Tissue, Liver, ATP, Mitochondrial disease, Exercise intolerance, PMM, Myalgia, Disorder, Adenosine triphosphate, Life, Deafness, Trial of the century, GLOBE, Investment, Guidelines International Network, Rhabdomyolysis, Encephalopathy, DNA, Home After Three Months Away, Muscle weakness, Heart, Prognosis, Pharmaceutical industry, Birth control, Nightclub, Dietary supplement

IRVINE, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the quarter ended September30, 2022.

Key Points: 
  • IRVINE, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the quarter ended September30, 2022.
  • We continued to advance our REN001 development programs during the third quarter, said Gregory J. Flesher, President and CEO of Reneo Pharmaceuticals.
  • We remain on track to announce topline data from this study in the fourth quarter of 2023.
  • Furthermore, we announced positive results from the Phase 1b study in long-chain fatty acid oxidation disorders (LC-FAOD) patients with nuclear DNA (nDNA) defects.

Final Results from Phase 2 INSTANT Trial of InRhythm™ for the Treatment of Newly Diagnosed and Recurrent Paroxysmal Atrial Fibrillation Presented at 2022 American Heart Association Scientific Sessions

Retrieved on: 
Monday, November 7, 2022
Atrial fibrillation, American Heart Association, Heart, Fatigue, Ageing, Lightheadedness, Chest pain, St. George's University, St George's, University of London, GLOBE, Degenerative disease, PAF, Population, Safety, Disease, Flecainide, Dizziness, Quality of life, Therapy, Stroke, Arrhythmia, Inhalation, Perspiration, Tachycardia-induced cardiomyopathy, SR, Palpitations, Medicine, Convenience, Prevalence, ECG, Pressure, Exercise intolerance, Hospital, Common, Ventricular fibrillation, AHA, Patient, AF, Pharmaceutical industry

SAN FRANCISCO, Nov. 07, 2022 (GLOBE NEWSWIRE) -- InCarda Therapeutics, Inc. (“InCarda”), a privately-held biopharmaceutical company developing inhaled therapies for cardiovascular diseases, today announced that final data from the company’s Phase 2 INSTANT trial of InRhythm (orally inhaled flecainide) were presented at the 2022 American Heart Association Scientific Sessions. The results were featured in a poster presentation entitled, “Orally Inhaled Flecainide for the Conversion of Recent-Onset, Symptomatic Atrial Fibrillation to Sinus Rhythm: Final Results from the Phase 2 INSTANT Trial,” at the conference, which is being held November 5-7, 2022 in Chicago.

Key Points: 
  • Final data demonstrated a conversion rate of approximately 47%, with a median time to conversion of less than 14 minutes from start of inhalation.
  • By Day 5, nearly all patients (97.3%) who converted to SR remained in SR without further treatment.
  • We are pleased to share the final results from the INSTANT study with the scientific community at the 2022 AHA Scientific Sessions.
  • The companyslead development product, InRhythm, is in Phase 3 development to treat acute episodes of PAF, a prevalent atrial arrhythmia.

CHOP Researchers to Lead Department of Defense Project to Measure Mitochondrial Function and Better Detect Mitochondrial Disease

Retrieved on: 
Tuesday, October 4, 2022
Movement, Department of Defense Serum Repository, Nanotechnology, Heart, Assistant, Infection, Hospital, Children's Hospital, University, Children's Hospital of Philadelphia, Traumatic brain injury, Disease, Gene, Health, Department, Mitochondrial disease, Exercise intolerance, Liver, Center, MD, Pediatrics, Mitochondrion, Weakness, PICU, Fatigue, CHOP, Ageing, Sepsis, United States Department of Defense, Falk, Stroke, Program, Pediatric intensive care unit, Exercise, Biomarker, Patient, Diagnosis, Philadelphia, Assistant Secretary of Defense for Health Affairs, Neurodegeneration, Division, Seizure, Disability in Canada, Exhaled breath condensate, Relative energy deficiency in sport, Medical device, Medical imaging, Vaccine, Defense, Child

PHILADELPHIA, Oct. 4, 2022 /PRNewswire/ -- Researchers at Children's Hospital of Philadelphia (CHOP) have received an $11.85 million Peer Reviewed Medical Research Program (PRMRP) Focused Program Award from the United States Department of Defense to develop and validate minimally invasive or noninvasive diagnostic techniques to quantify mitochondrial function in living people.

Key Points: 
  • "It is deeply exciting to think about the potential impact this work may have on the future of mitochondrial disease diagnosis and care," Falk said.
  • Since the disease has the potential to present in a variety of ways, mitochondrial disease is often very difficult to diagnose or is misdiagnosed entirely.
  • So far, more than 300 genes have been identified that are implicated in the development of mitochondrial disease.
  • Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Department of Defense.

Reneo Pharmaceuticals Announces Poster Presentations at the International Network for Fatty Acid Oxidation Research and Management Annual Meeting

Retrieved on: 
Monday, August 29, 2022
Muscle weakness, Lists of diseases, Security (finance), Mitochondrion, Total permanent disability insurance, Safety, INFORM, Hospital, Program, Disorder, Myopathy, Gene, Rhabdomyolysis, Brain, Disease, Death, Severe cognitive impairment, Tissue, Heart, PMM, Exercise intolerance, Deafness, DNA, Prognosis, Encephalopathy, A-DNA, U.S. Securities and Exchange Commission, Myalgia, Natural history, International Network of Health Promoting Hospitals and Health Services, GLOBE, Adenosine triphosphate, Nasdaq, Population, ATP, Adult, Parallel Walk Test, Liver, Hypoglycemia, Private Securities Litigation Reform Act, Lethargy, Metabolism, Sudden death, Mitochondrial trifunctional protein deficiency, Life, Patient, Pharmaceutical industry, Dietary supplement

The poster presentations highlight the results of two recently completed clinical trials in patients with long-chain fatty acid oxidation disorders (LC-FAOD), including a successful REN001 Phase 1b study and a non-interventional natural history study.

Key Points: 
  • The poster presentations highlight the results of two recently completed clinical trials in patients with long-chain fatty acid oxidation disorders (LC-FAOD), including a successful REN001 Phase 1b study and a non-interventional natural history study.
  • Improvements in 12-minute walk test distance and physical functioning scores were observed in a subgroup of patients.
  • The poster presentations elaborate on results first announced by the company in July 2022 and highlight the unmet medical need of patients with LC-FAOD.
  • REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation, and may increase production of new mitochondria.

Reneo Pharmaceuticals Reports Second Quarter 2022 Financial Results

Retrieved on: 
Tuesday, August 9, 2022
Death, U.S. Securities and Exchange Commission, Myopathy, Mitochondrial trifunctional protein deficiency, Disorder, Deafness, Gene, CEO, Sudden death, GLOBE, Private Securities Litigation Reform Act, Investment, Clinical trial, Brain, Encephalopathy, Myalgia, Achievement, Tissue, Enzyme, Home After Three Months Away, Life, ATP, Security (finance), PMM, Exercise intolerance, INFORM, Patient, DNA, Liver, A-DNA, Company, Prognosis, Hypoglycemia, Rhabdomyolysis, Lethargy, Program, Severe cognitive impairment, Mitochondrion, Total permanent disability insurance, STRIDE, Research, Protein, Muscle, Metabolism, Nasdaq, Heart, Conference, International Network of Health Promoting Hospitals and Health Services, Lists of diseases, Muscle weakness, Adenosine triphosphate, Pharmaceutical industry, Dietary supplement, Health insurance

IRVINE, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the quarter ended June30, 2022.

Key Points: 
  • IRVINE, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the quarter ended June30, 2022.
  • The second quarter was a very productive period for the company, highlighted by advancements in both of our mitochondrial disease programs, said Gregory J. Flesher, President and CEO of Reneo Pharmaceuticals.
  • The Company had approximately $127 million in cash, cash equivalents and short-term investments as of June30, 2022.
  • Research and development expenses for the three months ended June30, 2022 were $8.1 million, compared to $6.3 million for the three months ended June30, 2021.